Edap TMS SA recently published data showing that its Focal One high intensity focused ultrasound technology is non-inferior to radical prostatectomy as a first-line treatment for localized prostate ...

U.K. researchers at Nottingham Trent University, the University of Southampton and University Hospital Southampton and ...

Caliway Biopharmaceuticals’ lipolysis candidate, CBL-514, met all the primary and secondary efficacy endpoints in a phase IIb ...

Gynecological cancers with amplifications in the CCNE1 gene, which encodes cyclin E1, usually exhibit resistance to standard ...

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension ...

Researchers from Inovio Pharmaceuticals Inc. described the protective effect exerted by INO-4500, a DNA vaccine produced ...

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic polyadenylation element-binding 4 (CPEB4) gives ...

Relation Therapeutics Ltd. has delivered the first commercial validation of its combined wet lab/in silico platform for ...

The fact that both the U.S. Federal Trade Commission and the Department of Justice have oversight of mergers and acquisitions is something of a regulatory oddity. But David Balto, an attorney ...

Administrators at the U.S. Medicare program have proposed to cover the Cardiomems remote monitoring device for heart failure, ...

Sound Pharmaceuticals Inc.’s lead candidate, the anti-inflammatory SPI-1005 (ebselen), has produced positive pivotal phase ...

Europlaz Technologies Ltd. has developed a new neonatal flow sensor that could help improve neonatal care and save the lives ...